Insights
Rethinking Endometriosis
Endometriosis is having a scientific moment. After a century in which it was treated as a pelvic problem — and often not treated at all — researchers are re-describing it as a whole-body, inflammatory disease, developing diagnostics that don’t require surgery, and running the largest genetic studies the field has ever had. None of it is a cure. Together it changes what a doctor can look for, what a researcher can measure, and what you can reasonably ask for.
What Is Endometriosis?
An inflammatory disease in which tissue similar to the lining of the uterus — the endometrium — grows outside the uterus. That tissue responds to the hormonal changes of the menstrual cycle, thickening and breaking down just as it would inside the uterus, but with nowhere to go. The result is inflammation, scar tissue, and adhesions: bands of fibrous tissue that can make organs stick together.
Open a section below to read more. Nothing here is a substitute for a conversation with a clinician — it is meant to make that conversation shorter and sharper.
What is happening in the body4
The tissueEndometrium-like tissue, in the wrong place
The lesions are made of tissue similar to the uterine lining, growing outside the uterus. Because that tissue still answers to the hormones of the menstrual cycle, it builds up and breaks down on schedule — but the resulting blood and tissue have no way out of the body.
SourceWHO fact sheetThe damageInflammation, scar tissue, and adhesions
Trapped tissue drives chronic inflammation. Over time that inflammation lays down scar tissue and adhesions — fibrous bands that can bind organs to one another. This is why the disease is progressive for some people, and why pain can persist between periods rather than only during them.
SourceSmolarz, Szyłło & Romanowicz, 2021The symptomsFrom nothing at all to disabling
Inflammation from the lesions can produce severe pelvic pain, painful periods, fatigue, migraines, and gastrointestinal problems, among other symptoms. Severity varies enormously between individuals: some people with the condition never notice an indicator, while others find it debilitating in daily life. Symptom severity is a poor guide to how much disease is present — extensive lesions can cause little pain, and minimal lesions can cause a great deal.
SourceYale MedicineSmolarz et al., 20211960sThree clinical presentations, not one disease picture
With the introduction of laparoscopy in the early 1960s, three distinct clinical presentations of endometriosis were distinguished: peritoneal, deep adenomyotic, and cystic ovarian. That distinction still shapes how the disease is described and treated today — and it is part of why one person’s endometriosis can look so unlike another’s.
SourceBrosens & Benagiano, 2011 (NIH)Why so many go undiagnosed4
The delayAlmost seven years, on average, to a diagnosis
Many individuals experience symptoms for years before receiving a diagnosis. The average globally is close to seven years — a gap that reflects awareness, education, and access to care at least as much as it reflects biology.
SourceWHO fact sheetThe ageDiagnosed in the 30s and 40s — but it starts earlier
Endometriosis is most frequently diagnosed in people in their thirties and forties. Symptoms, however, commonly begin in adolescence. The distance between those two facts is the delay itself: teenage pain that is normalized, dismissed, or managed without ever being named.
SourceSmolarz et al., 2021FertilityA strong link to infertility
Between 25% and 50% of women experiencing infertility may have endometriosis. For many people, an infertility workup is the first time anyone looks for it — which means fertility care is doing diagnostic work that should have happened years earlier.
SourceSmolarz et al., 2021The countThe real number is almost certainly higher
Because a definitive diagnosis has often required invasive surgery — laparoscopy — and because symptoms are frequently normalized or misdiagnosed as something else, the number of people actually affected is likely higher than any published figure. Prevalence estimates measure rate of diagnosis, not disease.
SourceSmolarz et al., 2021Explore further
What Is Changing
Seven findings from the last few years, each stated plainly and linked to its source. Open any one to read more.
GeneticsUp to 80 risk regions identified in the largest genomic study yet
Large genomic studies, including a major Yale-led analysis published in Nature Genetics, have identified up to 80 regions of the genome linked to endometriosis risk. That is a step change in a field that a decade ago had a handful of candidate loci — and it gives drug developers something concrete to aim at.
SourcesPubMedYale School of MedicineInheritanceShared risk with inflammatory conditions and adenomyosis
Those risk regions overlap with inflammatory conditions and with adenomyosis — evidence that endometriosis sits inside a family of related disorders rather than standing alone. It is also the research behind the growing clinical interest in family history.
SourcesPubMedYale School of MedicineWhole bodyA systemic condition, not a localized pelvic issue
Researchers increasingly view endometriosis as a systemic condition involving chronic inflammation and immune dysfunction, rather than a problem confined to the pelvis. This is the single biggest conceptual change in the field, and it reaches the exam room: it reframes fatigue, migraines, and gut symptoms as part of the disease rather than as unrelated complaints.
SourcePubMedWhole bodyLinks to arthritis and cardiovascular stress
Emerging research points to systemic links between endometriosis and wider conditions including arthritis and cardiovascular stress — consistent with a disease driven by chronic inflammation. The practical implication is long-term: endometriosis may be worth factoring into general health monitoring, not only reproductive care.
SourceYale MedicineDiagnosticsEpigenetic blood tests to predict who responds to which drug
Researchers are developing blood tests that read epigenetic markers — methylation patterns in white blood cells — to predict whether a patient will be resistant to standard progesterone-based hormonal treatment. The goal is to let patients skip the trial-and-error phase, which today can consume months or years of a life while symptoms continue.
SourceYale School of MedicineTreatmentGnRH antagonists: pain relief with fewer side effects
Newer oral medications in the GnRH antagonist class suppress pain effectively while minimizing the severe estrogen-deprivation side effects that made earlier hormonal treatments hard to tolerate. Several are now in clinical use; the choice between them turns on dosing, add-back therapy, and individual response.
Alongside them, investigations into repurposing existing drugs, into gut microbiome influences, and into anti-inflammatory compounds all aim at the same gap: symptom management that does not depend on hormones.
SourcesPatient Care OnlineNews-MedicalMDPIJanuary 2026Therapeutic mRNA aimed at endometriosis-related infertility
Researchers at Johns Hopkins Medicine reported early success using therapeutic mRNA to target endometriosis-related infertility. Published in Nature Nanotechnology, the study marks a shift from using mRNA solely for vaccines to using it as a localized, corrective therapy for reproductive disorders.
This matters because people with endometriosis have historically had lower success rates with assisted reproductive technologies such as IVF. The work is early — it is not a treatment you can ask for yet — but it opens a path that did not previously exist.
SourceJohns Hopkins Medicine
